(Q45368933)

English

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients

scientific article published in March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chien-Hung Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Chuan-Mo Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Chao-Hung Hung

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Jing-Houng Wang

4

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Tsung-Hui Hu

5

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Chi-Sin Changchien

6

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sheng-Nan Lu

7

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

461-468

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Hepatitis B: the disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Natural history of chronic hepatitis B virus infection: an immunopathological study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Prevalence and clinical implications of hepatitis B virus genotypes in southern Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06429.X

21 January 2018

Identifiers

10.1111/J.1440-1746.2010.06429.X

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45368933&oldid=2075913025"